Triazine Kinase Inhibitors for Selective Syk Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions such as restenosis and inflammatory diseases lack effective inhibitors of Syk kinase, and there is a need for compounds that selectively inhibit Syk without affecting other kinases.
Innovation Solution
Development of novel triazine compounds that act as specific inhibitors of Syk kinase, formulated into pharmaceutical compositions for treating cardiovascular disease, inflammatory disease, and autoimmune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for restenosis and inflammatory diseases are used, then existing therapeutic options are available, but effective Syk kinase inhibition is lacking
Solution Approach 1:
The patent segments the broad kinase family into specific subclasses, focusing on Syk kinase inhibition while distinguishing it from other kinases. The compounds are designed to target specific structural features of Syk kinase, enabling selective inhibition of this particular enzyme while leaving other kinases unaffected.
Solution Approach 2:
The invention introduces specific local chemical modifications to the triazine core structure, including particular substituent patterns and functional groups that confer selective affinity for Syk kinase. These localized structural features enable the compounds to interact specifically with Syk kinase binding sites, providing reliable Syk inhibition without broad kinase suppression.
2Adaptability or versatility
If broad kinase inhibitors are used, then multiple kinase activities are inhibited, but selective Syk inhibition is not achieved
Solution Approach 1:
The patent employs local quality by introducing specific substituent patterns on the triazine ring system, including particular arrangements of electron-withdrawing and electron-donating groups. These localized structural modifications create a binding profile that is highly selective for Syk kinase, allowing the compounds to distinguish Syk from other kinases based on subtle differences in their active site architectures.
Solution Approach 2:
The invention utilizes asymmetric substitution patterns on the triazine core, where substituents are placed at specific positions rather than symmetrically. This asymmetry creates a chiral or prochiral environment in the binding interface, enabling the compounds to discriminate between the asymmetric binding pockets of different kinases, thereby achieving high Syk selectivity.
3Measurement precision
If novel triazine compounds are developed for Syk inhibition, then selective Syk targeting is achieved, but comprehensive treatment coverage for multiple conditions is limited
Solution Approach 1:
The patent demonstrates universality by showing that the same class of triazine compounds can treat multiple distinct conditions including restenosis, inflammatory diseases, and autoimmune disorders. The compounds achieve this multi-functionality by selectively inhibiting Syk kinase, which is a common downstream target in the signaling pathways of all these different diseases, thereby providing a unified therapeutic mechanism for diverse conditions.
Data Source
AI summary
Provided are triazine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.